NasdaqGS:PGEN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Precigen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PGEN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

PGEN

-2.5%

US Biotechs

-4.1%

US Market


1 Year Return

-14.4%

PGEN

25.0%

US Biotechs

12.0%

US Market

Return vs Industry: PGEN underperformed the US Biotechs industry which returned 25% over the past year.

Return vs Market: PGEN underperformed the US Market which returned 12% over the past year.


Shareholder returns

PGENIndustryMarket
7 Day0%-2.5%-4.1%
30 Day25.4%-2.1%-0.2%
90 Day4.3%-1.8%2.8%
1 Year-14.4%-14.4%27.1%25.0%14.6%12.0%
3 Year-73.3%-73.3%18.0%12.0%35.8%26.8%
5 Year-88.7%-88.7%8.9%1.0%75.2%55.6%

Price Volatility Vs. Market

How volatile is Precigen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Precigen undervalued compared to its fair value and its price relative to the market?

15.27x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PGEN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PGEN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PGEN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: PGEN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PGEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PGEN is overvalued based on its PB Ratio (15.3x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Precigen forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

19.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PGEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PGEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PGEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PGEN's revenue is expected to decline over the next 3 years (-4.8% per year).

High Growth Revenue: PGEN's revenue is forecast to decline over the next 3 years (-4.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PGEN is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Precigen performed over the past 5 years?

-23.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PGEN is currently unprofitable.

Growing Profit Margin: PGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PGEN is unprofitable, and losses have increased over the past 5 years at a rate of 23.6% per year.

Accelerating Growth: Unable to compare PGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.8%).


Return on Equity

High ROE: PGEN has a negative Return on Equity (-395.32%), as it is currently unprofitable.


Next Steps

Financial Health

How is Precigen's financial position?


Financial Position Analysis

Short Term Liabilities: PGEN's short term assets ($173.0M) exceed its short term liabilities ($64.1M).

Long Term Liabilities: PGEN's short term assets ($173.0M) do not cover its long term liabilities ($248.1M).


Debt to Equity History and Analysis

Debt Level: PGEN's debt to equity ratio (450.8%) is considered high.

Reducing Debt: PGEN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PGEN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PGEN has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 31.9% each year.


Next Steps

Dividend

What is Precigen current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.0yrs

Average management tenure


CEO

Helen Sabzevari (58 yo)

0.75

Tenure

US$1,465,107

Compensation

Dr. Helen Sabzevari, Ph.D., MPH, has been President and Chief Executive Officer of Precigen, Inc (formerly Intrexon Corporation) since January 2, 2020 and has been its Director since June 19, 2020. He serv ...


CEO Compensation Analysis

Compensation vs Market: Helen's total compensation ($USD1.47M) is below average for companies of similar size in the US market ($USD2.96M).

Compensation vs Earnings: Helen's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Randal Kirk
Executive Chairman12.58yrsUS$2.07m9.82%
$ 77.1m
Helen Sabzevari
President0.75yrUS$1.47m0.23%
$ 1.8m
Rick Sterling
Chief Financial Officer13.75yrsUS$1.50m0.17%
$ 1.3m
Donald Lehr
Chief Legal Officer & Corporate Secretary9.75yrsUS$1.56m0.14%
$ 1.1m
Jeffrey Perez
Senior Vice President of Intellectual Property Affairs6.17yrsUS$1.48m0.14%
$ 1.1m
Thomas Reed
Founder & Chief Science Officer22.75yrsUS$572.72k0.14%
$ 1.1m
Rutul Shah
Head of Operations & Portfoliono datano datano data
Steven Harasym
Head of Investor Relations2.75yrsno datano data
Marie Rossi
Vice President of Communicationsno datano datano data
Rob Russell
Head of Human Resourcesno datano datano data
Tom Samuelson
Head of Financial Strategyno datano datano data
Douglas Brough
Head of Researchno datano datano data

8.0yrs

Average Tenure

56yo

Average Age

Experienced Management: PGEN's management team is seasoned and experienced (8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Randal Kirk
Executive Chairman12.58yrsUS$2.07m9.82%
$ 77.1m
Helen Sabzevari
President0.75yrUS$1.47m0.23%
$ 1.8m
Jeffrey Kindler
Independent Director8.92yrsUS$319.00k0.080%
$ 628.1k
Fred Hassan
Independent Director4.33yrsUS$306.50k0.048%
$ 373.9k
Cesar Alvarez
Independent Director12.58yrsUS$312.50k0.10%
$ 808.3k
Robert Shapiro
Lead Independent Directorno dataUS$312.99k0.12%
$ 906.6k
James Turley
Independent Director6.5yrsUS$312.49k0.050%
$ 393.4k
Dean Mitchell
Independent Director11.58yrsUS$306.50k0.059%
$ 462.9k
Steven Frank
Independent Director12.58yrsUS$299.99k0.15%
$ 1.2m
Vinita Gupta
Independent Director3.5yrsUS$306.50k0.045%
$ 356.9k

8.9yrs

Average Tenure

64.5yo

Average Age

Experienced Board: PGEN's board of directors are considered experienced (8.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.3%.


Top Shareholders

Company Information

Precigen, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Precigen, Inc.
  • Ticker: PGEN
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$784.417m
  • Shares outstanding: 178.68m
  • Website: https://www.precigen.com

Number of Employees


Location

  • Precigen, Inc.
  • 20374 Seneca Meadows Parkway
  • Germantown
  • Maryland
  • 20876
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PGENNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 2013
I5XDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2013

Biography

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/30 04:30
End of Day Share Price2020/10/29 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.